Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 1998 Aug;106(8):447–457. doi: 10.1289/ehp.98106447

Risk assessment of thyroid follicular cell tumors.

R N Hill 1, T M Crisp 1, P M Hurley 1, S L Rosenthal 1, D V Singh 1
PMCID: PMC1533213  PMID: 9681971

Abstract

Thyroid follicular cell tumors arise in rodents from mutations, perturbations of thyroid and pituitary hormone status with increased stimulation of thyroid cell growth by thyroid-stimulating hormone (TSH), or a combination of the two. The only known human thyroid carcinogen is ionizing radiation. It is not known for certain whether chemicals that affect thyroid cell growth lead to human thyroid cancer. The U.S. Environmental Protection Agency applies the following science policy positions: 1) chemically induced rodent thyroid tumors are presumed to be relevant to humans; 2) when interspecies information is lacking, the default is to assume comparable carcinogenic sensitivity in rodents and humans; 3) adverse rodent noncancer thyroid effects due to chemically induced thyroid-pituitary disruption are presumed to be relevant to humans; 4) linear dose-response considerations are applied to thyroid cancer induced by chemical substances that either do not disrupt thyroid functioning or lack mode of action information; 5) nonlinear thyroid cancer dose-response considerations are applied to chemicals that reduce thyroid hormone levels, increase TSH and thyroid cell division, and are judged to lack mutagenic activity; and 6) nonlinear considerations may be applied in thyroid cancer dose-response assessments on a case-by-case basis for chemicals that disrupt thyroid-pituitary functioning and demonstrate some mutagenic activity. Required data for risk assessment purposes is mode of action information on mutagenicity, increases in follicular cell growth (cell size and number) and thyroid gland weight, thyroid-pituitary hormones, site of action, correlations between doses producing thyroid effects and cancer, and reversibility of effects when dosing ceases.

Full text

PDF
447

Images in this article

448Figure 1
on p.448
449Figure 2
on p.449
452Figure 3
on p.452

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BIELSCHOWSKY F. Neoplasia and internal environment. Br J Cancer. 1955 Mar;9(1):80–116. doi: 10.1038/bjc.1955.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Belfiore A., Garofalo M. R., Giuffrida D., Runello F., Filetti S., Fiumara A., Ippolito O., Vigneri R. Increased aggressiveness of thyroid cancer in patients with Graves' disease. J Clin Endocrinol Metab. 1990 Apr;70(4):830–835. doi: 10.1210/jcem-70-4-830. [DOI] [PubMed] [Google Scholar]
  3. Boice J. D., Jr Cancer following irradiation in childhood and adolescence. Med Pediatr Oncol Suppl. 1996;1:29–34. [PubMed] [Google Scholar]
  4. Bondeson L., Ljungberg O. Occult papillary thyroid carcinoma in the young and the aged. Cancer. 1984 Apr 15;53(8):1790–1792. doi: 10.1002/1097-0142(19840415)53:8<1790::aid-cncr2820530831>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  5. Boring C. C., Squires T. S., Tong T., Montgomery S. Cancer statistics, 1994. CA Cancer J Clin. 1994 Jan-Feb;44(1):7–26. doi: 10.3322/canjclin.44.1.7. [DOI] [PubMed] [Google Scholar]
  6. Brent G. A. The molecular basis of thyroid hormone action. N Engl J Med. 1994 Sep 29;331(13):847–853. doi: 10.1056/NEJM199409293311306. [DOI] [PubMed] [Google Scholar]
  7. Capen C. C., Dayan A. D., Green S. Receptor-mediated mechanisms in carcinogenesis: an overview. Mutat Res. 1995 Dec;333(1-2):215–224. doi: 10.1016/0027-5107(95)00148-4. [DOI] [PubMed] [Google Scholar]
  8. Capen C. C., Martin S. L. The effects of xenobiotics on the structure and function of thyroid follicular and C-cells. Toxicol Pathol. 1989;17(2):266–293. doi: 10.1177/019262338901700205. [DOI] [PubMed] [Google Scholar]
  9. Capen C. C. Mechanisms of chemical injury of thyroid gland. Prog Clin Biol Res. 1994;387:173–191. [PubMed] [Google Scholar]
  10. Capen C. C. Pathophysiology of chemical injury of the thyroid gland. Toxicol Lett. 1992 Dec;64-65 Spec No:381–388. doi: 10.1016/0378-4274(92)90211-2. [DOI] [PubMed] [Google Scholar]
  11. Chanoine J. P., Braverman L. E., Farwell A. P., Safran M., Alex S., Dubord S., Leonard J. L. The thyroid gland is a major source of circulating T3 in the rat. J Clin Invest. 1993 Jun;91(6):2709–2713. doi: 10.1172/JCI116510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Chen H. J. Age and sex difference in serum and pituitary thyrotropin concentrations in the rat: influence by pituitary adenoma. Exp Gerontol. 1984;19(1):1–6. doi: 10.1016/0531-5565(84)90025-1. [DOI] [PubMed] [Google Scholar]
  13. Christov K., Raichev R. Experimental thyroid carcinogenesis. Curr Top Pathol. 1972;56:79–114. doi: 10.1007/978-3-642-65324-7_3. [DOI] [PubMed] [Google Scholar]
  14. Crump K. S., Hoel D. G., Langley C. H., Peto R. Fundamental carcinogenic processes and their implications for low dose risk assessment. Cancer Res. 1976 Sep;36(9 PT1):2973–2979. [PubMed] [Google Scholar]
  15. Curran P. G., DeGroot L. J. The effect of hepatic enzyme-inducing drugs on thyroid hormones and the thyroid gland. Endocr Rev. 1991 May;12(2):135–150. doi: 10.1210/edrv-12-2-135. [DOI] [PubMed] [Google Scholar]
  16. DONIACH I. The effect of radioactive iodine alone and in combination with methylthiouracil upon tumour production in the rat's thyroid gland. Br J Cancer. 1953 Jun;7(2):181–202. doi: 10.1038/bjc.1953.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Döhler K. D., Wong C. C., von zur Mühlen A. The rat as model for the study of drug effects on thyroid function: consideration of methodological problems. Pharmacol Ther B. 1979;5(1-3):305–318. doi: 10.1016/0163-7258(79)90099-8. [DOI] [PubMed] [Google Scholar]
  18. Eltom M., Salih M. A., Boström H., Dahlberg P. A. Differences in aetiology and thyroid function in endemic goitre between rural and urban areas of the Darfur region of the Sudan. Acta Endocrinol (Copenh) 1985 Mar;108(3):356–360. doi: 10.1530/acta.0.1080356. [DOI] [PubMed] [Google Scholar]
  19. Farid N. R., Shi Y., Zou M. Molecular basis of thyroid cancer. Endocr Rev. 1994 Apr;15(2):202–232. doi: 10.1210/edrv-15-2-202. [DOI] [PubMed] [Google Scholar]
  20. Galanti M. R., Sparén P., Karlsson A., Grimelius L., Ekbom A. Is residence in areas of endemic goiter a risk factor for thyroid cancer? Int J Cancer. 1995 May 29;61(5):615–621. doi: 10.1002/ijc.2910610506. [DOI] [PubMed] [Google Scholar]
  21. HERSHMAN J. M. Effect of various compounds on the binding of thyroxine to serum proteins in the rat. Endocrinology. 1963 May;72:799–803. doi: 10.1210/endo-72-5-799. [DOI] [PubMed] [Google Scholar]
  22. Hard G. C. Recent developments in the investigation of thyroid regulation and thyroid carcinogenesis. Environ Health Perspect. 1998 Aug;106(8):427–436. doi: 10.1289/ehp.106-1533202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hasegawa R., Shirai T., Hakoi K., Wada S., Yamaguchi K., Takayama S. Synergistic enhancement of thyroid tumor induction by 2,4-diaminoanisole sulfate, N,N'-diethylthiourea and 4,4'-thiodianiline in male F344 rats. Carcinogenesis. 1991 Aug;12(8):1515–1518. doi: 10.1093/carcin/12.8.1515. [DOI] [PubMed] [Google Scholar]
  24. Haseman J. K., Lockhart A. M. Correlations between chemically related site-specific carcinogenic effects in long-term studies in rats and mice. Environ Health Perspect. 1993 Apr 22;101(1):50–54. doi: 10.1289/ehp.9310150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Hiasa Y., Kitahori Y., Kitamura M., Nishioka H., Yane K., Fukumoto M., Ohshima M., Nakaoka S., Nishii S. Relationships between serum thyroid stimulating hormone levels and development of thyroid tumors in rats treated with N-bis-(2-hydroxypropyl)nitrosamine. Carcinogenesis. 1991 May;12(5):873–877. doi: 10.1093/carcin/12.5.873. [DOI] [PubMed] [Google Scholar]
  26. Hill R. N., Erdreich L. S., Paynter O. E., Roberts P. A., Rosenthal S. L., Wilkinson C. F. Thyroid follicular cell carcinogenesis. Fundam Appl Toxicol. 1989 May;12(4):629–697. [PubMed] [Google Scholar]
  27. Hoel D. G., Portier C. J. Nonlinearity of dose-response functions for carcinogenicity. Environ Health Perspect. 1994 Jan;102 (Suppl 1):109–113. doi: 10.1289/ehp.94102s1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Holm L. E., Wiklund K. E., Lundell G. E., Bergman N. A., Bjelkengren G., Cederquist E. S., Ericsson U. B., Larsson L. G., Lidberg M. E., Lindberg R. S. Thyroid cancer after diagnostic doses of iodine-131: a retrospective cohort study. J Natl Cancer Inst. 1988 Sep 21;80(14):1132–1138. doi: 10.1093/jnci/80.14.1132. [DOI] [PubMed] [Google Scholar]
  29. Hurley P. M. Mode of carcinogenic action of pesticides inducing thyroid follicular cell tumors in rodents. Environ Health Perspect. 1998 Aug;106(8):437–445. doi: 10.1289/ehp.98106437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Ivy A. C. Biology of Cancer. Science. 1947 Nov 14;106(2759):455–460. doi: 10.1126/science.106.2759.455. [DOI] [PubMed] [Google Scholar]
  31. Jemec B. Studies of the goitrogenic and tumorigenic effect of two goitrogens in combination with hypophysectomy or thyroid hormone treatment. Cancer. 1980 Apr 15;45(8):2138–2148. doi: 10.1002/1097-0142(19800415)45:8<2138::aid-cncr2820450822>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  32. Kohn M. C., Sewall C. H., Lucier G. W., Portier C. J. A mechanistic model of effects of dioxin on thyroid hormones in the rat. Toxicol Appl Pharmacol. 1996 Jan;136(1):29–48. doi: 10.1006/taap.1996.0004. [DOI] [PubMed] [Google Scholar]
  33. Lomat L., Galburt G., Quastel M. R., Polyakov S., Okeanov A., Rozin S. Incidence of childhood disease in Belarus associated with the Chernobyl accident. Environ Health Perspect. 1997 Dec;105 (Suppl 6):1529–1532. doi: 10.1289/ehp.97105s61529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. MORRIS H. P. The experimental development and metabolism of thyroid gland tumors. Adv Cancer Res. 1955;3:51–115. doi: 10.1016/s0065-230x(08)60918-5. [DOI] [PubMed] [Google Scholar]
  35. MORTENSEN J. D., WOOLNER L. B., BENNETT W. A. Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab. 1955 Oct;15(10):1270–1280. doi: 10.1210/jcem-15-10-1270. [DOI] [PubMed] [Google Scholar]
  36. Mazzaferri E. L. Management of a solitary thyroid nodule. N Engl J Med. 1993 Feb 25;328(8):553–559. doi: 10.1056/NEJM199302253280807. [DOI] [PubMed] [Google Scholar]
  37. Mazzaferri E. L. Thyroid cancer and Graves' disease. J Clin Endocrinol Metab. 1990 Apr;70(4):826–829. doi: 10.1210/jcem-70-4-826. [DOI] [PubMed] [Google Scholar]
  38. McClain R. M. Mechanistic considerations for the relevance of animal data on thyroid neoplasia to human risk assessment. Mutat Res. 1995 Dec;333(1-2):131–142. doi: 10.1016/0027-5107(95)00139-5. [DOI] [PubMed] [Google Scholar]
  39. McClain R. M., Posch R. C., Bosakowski T., Armstrong J. M. Studies on the mode of action for thyroid gland tumor promotion in rats by phenobarbital. Toxicol Appl Pharmacol. 1988 Jun 30;94(2):254–265. doi: 10.1016/0041-008x(88)90267-0. [DOI] [PubMed] [Google Scholar]
  40. McClain R. M. The significance of hepatic microsomal enzyme induction and altered thyroid function in rats: implications for thyroid gland neoplasia. Toxicol Pathol. 1989;17(2):294–306. doi: 10.1177/019262338901700206. [DOI] [PubMed] [Google Scholar]
  41. McClain R. M. Thyroid gland neoplasia: non-genotoxic mechanisms. Toxicol Lett. 1992 Dec;64-65 Spec No:397–408. doi: 10.1016/0378-4274(92)90213-4. [DOI] [PubMed] [Google Scholar]
  42. McConnell E. E. Thyroid follicular cell carcinogenesis: results from 343 2-year carcinogenicity studies conducted by the NCI/NTP. Regul Toxicol Pharmacol. 1992 Oct;16(2):177–188. doi: 10.1016/0273-2300(92)90056-f. [DOI] [PubMed] [Google Scholar]
  43. McTiernan A. M., Weiss N. S., Daling J. R. Incidence of thyroid cancer in women in relation to previous exposure to radiation therapy and history of thyroid disease. J Natl Cancer Inst. 1984 Sep;73(3):575–581. [PubMed] [Google Scholar]
  44. Meier K. L., Bailer A. J., Portier C. J. A measure of tumorigenic potency incorporating dose-response shape. Biometrics. 1993 Sep;49(3):917–926. [PubMed] [Google Scholar]
  45. Murthy A. S., Russfield A. B., Snow G. J. Effect of 4,4'-oxydianiline on the thyroid and pituitary glands of F344 rats: a morphologic study with the use of the immunoperoxidase method. J Natl Cancer Inst. 1985 Jan;74(1):203–208. [PubMed] [Google Scholar]
  46. OPPENHEIMER J. H., TAVERNETTI R. R. Displacement of thyroxine from human thyroxine-binding globulin by analogues of hydantoin. Steric aspects of the thyroxinebinding site. J Clin Invest. 1962 Dec;41:2213–2220. doi: 10.1172/JCI104680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Olsen J. H., Boice J. D., Jr, Jensen J. P., Fraumeni J. F., Jr Cancer among epileptic patients exposed to anticonvulsant drugs. J Natl Cancer Inst. 1989 May 10;81(10):803–808. doi: 10.1093/jnci/81.10.803. [DOI] [PubMed] [Google Scholar]
  48. Oppenheimer J. H. Thyroid hormone action at the cellular level. Science. 1979 Mar 9;203(4384):971–979. doi: 10.1126/science.218285. [DOI] [PubMed] [Google Scholar]
  49. Owen N. V., Worth H. M., Kiplinger G. F. The effects of long-term ingestion of methimazole on the thyroids of rats. Food Cosmet Toxicol. 1973 Aug;11(4):649–653. doi: 10.1016/s0015-6264(73)80336-0. [DOI] [PubMed] [Google Scholar]
  50. Paynter O. E., Burin G. J., Jaeger R. B., Gregorio C. A. Goitrogens and thyroid follicular cell neoplasia: evidence for a threshold process. Regul Toxicol Pharmacol. 1988 Mar;8(1):102–119. doi: 10.1016/0273-2300(88)90009-8. [DOI] [PubMed] [Google Scholar]
  51. Pitot H. C., Dragan Y. P. Facts and theories concerning the mechanisms of carcinogenesis. FASEB J. 1991 Jun;5(9):2280–2286. [PubMed] [Google Scholar]
  52. Poulsen E. Case study: erythrosine. Food Addit Contam. 1993 May-Jun;10(3):315–323. doi: 10.1080/02652039309374154. [DOI] [PubMed] [Google Scholar]
  53. Refetoff S., Weiss R. E., Usala S. J. The syndromes of resistance to thyroid hormone. Endocr Rev. 1993 Jun;14(3):348–399. doi: 10.1210/edrv-14-3-348. [DOI] [PubMed] [Google Scholar]
  54. Ridgway E. C. Clinical review 30: Clinician's evaluation of a solitary thyroid nodule. J Clin Endocrinol Metab. 1992 Feb;74(2):231–235. doi: 10.1210/jcem.74.2.1730801. [DOI] [PubMed] [Google Scholar]
  55. Ron E., Kleinerman R. A., Boice J. D., Jr, LiVolsi V. A., Flannery J. T., Fraumeni J. F., Jr A population-based case-control study of thyroid cancer. J Natl Cancer Inst. 1987 Jul;79(1):1–12. [PubMed] [Google Scholar]
  56. Ron E., Modan B., Preston D., Alfandary E., Stovall M., Boice J. D., Jr Thyroid neoplasia following low-dose radiation in childhood. Radiat Res. 1989 Dec;120(3):516–531. [PubMed] [Google Scholar]
  57. Said S., Schlumberger M., Suarez H. G. Oncogenes and anti-oncogenes in human epithelial thyroid tumors. J Endocrinol Invest. 1994 May;17(5):371–379. doi: 10.1007/BF03349004. [DOI] [PubMed] [Google Scholar]
  58. Studer H., Derwahl M. Mechanisms of nonneoplastic endocrine hyperplasia--a changing concept: a review focused on the thyroid gland. Endocr Rev. 1995 Aug;16(4):411–426. doi: 10.1210/edrv-16-4-411. [DOI] [PubMed] [Google Scholar]
  59. Surks M. I., Chopra I. J., Mariash C. N., Nicoloff J. T., Solomon D. H. American Thyroid Association guidelines for use of laboratory tests in thyroid disorders. JAMA. 1990 Mar 16;263(11):1529–1532. [PubMed] [Google Scholar]
  60. Thomas G. A., Williams E. D. Evidence for and possible mechanisms of non-genotoxic carcinogenesis in the rodent thyroid. Mutat Res. 1991 Jun;248(2):357–370. doi: 10.1016/0027-5107(91)90068-y. [DOI] [PubMed] [Google Scholar]
  61. Todd G. C. Induction and reversibility of thyroid proliferative changes in rats given an antithyroid compound. Vet Pathol. 1986 Mar;23(2):110–117. doi: 10.1177/030098588602300202. [DOI] [PubMed] [Google Scholar]
  62. Vickery A. L., Jr The diagnosis of malignancy in dyshormonogenetic goitre. Clin Endocrinol Metab. 1981 Jul;10(2):317–335. doi: 10.1016/s0300-595x(81)80025-4. [DOI] [PubMed] [Google Scholar]
  63. Williams E. D. Cell proliferation and thyroid neoplasia. Toxicol Lett. 1992 Dec;64-65 Spec No:375–379. doi: 10.1016/0378-4274(92)90210-b. [DOI] [PubMed] [Google Scholar]
  64. Williams E. D. Mechanisms and pathogenesis of thyroid cancer in animals and man. Mutat Res. 1995 Dec;333(1-2):123–129. doi: 10.1016/0027-5107(95)00138-7. [DOI] [PubMed] [Google Scholar]
  65. Wynford-Thomas D., Stringer B. M., Williams E. D. Desensitisation of rat thyroid to the growth-stimulating action of TSH during prolonged goitrogen administration. Persistence of refractoriness following withdrawal of stimulation. Acta Endocrinol (Copenh) 1982 Dec;101(4):562–569. doi: 10.1530/acta.0.1010562. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of American Chemical Society

RESOURCES